Osteoporosis in older people: A tale of two studies (and three treatments)

Journal of the American Geriatrics Society

Volumn 54, Issue 5, 2006, Pages 853-855

  Troen, Bruce R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; COLECALCIFEROL; ESTROGEN; GLUCOCORTICOID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE; ETIDRONIC ACID;

CLINICAL TRIAL; DRUG SAFETY; EDITORIAL; FRACTURE; HIP FRACTURE; HUMAN; HYPERCALCEMIA; OSTEOPOROSIS; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; AGED; FEMALE; MALE; NOTE;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; TERIPARATIDE; VITAMIN D;

EID: 33745008855     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2006.00699.x     Document Type: Editorial

References (37)

1. Hodsman AB, Bauer DC, Dempster DW et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
2. Reeve J, Meunier PJ, Parsons JA et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. BMJ 1980;280:1340-1344.
3. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
4. Orwoll ES, Scheele WH, Paul S et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9-17.
5. Lane NE, Sanchez S, Modin GW et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998;102:1627-1633.
6. Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 2001;16:1846-1853.
7. Uusi-Rasi K, Semanick LM, Zanchetta JR et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005;36:948-958.
8. Hagino H, Okano T, Akhter MP et al. Effect of parathyroid hormone on cortical bone response to in vivo external loading of the rat tibia. J Bone Miner Metab 2001;19:244-250.
9. Marcus R, Wang O, Satterwhite J et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23.
10. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf) 2005;62:265-281.
11. Holick MF. The vitamin D epidemic and its health consequences. J Nutr 2005;135:2739S-2748S.
12. Dawson-Hughes B, Heaney RP, Holick MF et al. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-716.
13. Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-1460.
14. Rosen CJ. What's new with PTH in osteoporosis: Where are we and where are we headed? Trends Endocrinol Metab 2004;15:229-233.
15. Srivastava AK, Vliet EL, Lewiecki EM et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005;21:1015-1026.
16. Ishijima M, Yamanaka M, Sakamoto Y et al. Vitamin D insufficiency impairs the effect of alendronate for the treatment of osteoporosis in postmenopausal women. J Bone Miner Res 2005;20(Suppl 1):S296.
17. Antoniucci DM, Vittinghoff E, Blackwell T et al. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 2005;90:4566-4572.
18. Bischoff-Ferrari HA, Dietrich T, Orav EJ et al. Positive association between 25-hydroxy vitamin D levels and bone mineral density: A population-based study of younger and older adults. Am J Med 2004;116:634-639.
19. Aloia JF, Talwar SA, Pollack S et al. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med 2005;165:1618-1623.
20. Moore C, Murphy MM, Keast DR et al. Vitamin D intake in the United States. J Am Diet Assoc 2004;104:980-983.
21. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 2005;293:2257-2264.
22. Heaney RP. To D or not to D [on-line]. Available at www.ammom.com.mx/ AMMOM/OsteoKey/To_D_or_not_to_D.pdf Bonekey-Osteovision Accessed January 27, 2006.
23. Venning G. Recent developments in vitamin D deficiency and muscle weakness among elderly people. BMJ 2005;330:524-526.
24. Wilkins CH, Birge SJ. Prevention of osteoporotic fractures in the elderly. Am J Med 2005;118:1190-1195.
25. Levis S, Gomez A, Jimenez C et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab 2005;90:1557-1562.
26. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. Effect of vitamin D on falls: A meta-analysis. JAMA 2004;291:1999-2006.
27. Bischoff-Ferrari HA, Dietrich T, Orav EJ et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or = 60 y. Am J Clin Nutr 2004;80:752-758.
28. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: A review. Altern Med Rev 2005;10:94-111.
29. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-65.
30. Lane NE, Gore LR, Cummings SR et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: A longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum 1999;42:854-860.
31. Dietrich T, Joshipura KJ, Dawson-Hughes B et al. Association between serum concentrations of 25-hydroxyvitamin D3 and periodontal disease in the US population. Am J Clin Nutr 2004;80:108-113.
32. Ford ES, Ajani UA, McGuire LC et al. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005;28:1228-1230.
33. Snijder MB, van Dam RM, Visser M et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: A population-based study in older men and women. J Clin Endocrinol Metab 2005;90:4119-4123.
34. Chiu KC, Chu A, Go VL et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-825.
35. Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol 2005;97:13-19.
36. Ish-Shalom S, Salganik T, Segal E et al. Daily, weekly or monthly protocols to reach the desired serum 25-hydroxyvitamin D concentration for the elderly. J Bone Miner Res 2005;20(Suppl 1):S288.
37. Mocanu V, Stitt PA, Costan A et al. Safety and bone mineral density effects of bread fortified with 125 mcg vitamin D3/day in Romanian nursing-home residents. J Bone Miner Res 2005;20(Suppl 1):S288.